The application of artificial intelligence (AI) in biomedicine has increased substantially since 2010 and has the potential to revolutionize the discovery of disease targets and therapies in the future.
In the opening keynote lecture of the WMS 2021 virtual congress, Dr Brendan Frey, the Founder, CEO and Chief Engineer of Deep Genomics, Toronto, Canada, discussed the application of AI and the work of Deep Genomics using AI in the discovery of potential disease targets and therapies.
Dr Frey began by explaining that AI, using computers that act intelligently, encompasses machine learning (AI that learns from experience) and deep learning (machine learning that uses a neural network composed of many layers of interconnected artificial neurons).